MatchMedi
한국어

Curated clinical source

NRAS-mutant melanoma

What to ask when melanoma testing reports an NRAS mutation, with clinical claims tied back to NCI PDQ and trial-source navigation.

Clinical source
Melanoma Treatment (PDQ) - Health Professional Version
Publisher
National Cancer Institute
Reuse posture
open-embed
Last checked
2026-05-20

An NRAS result is a reason to ask more precise questions, not a reason to panic alone with search results. This page keeps the clinical framing tied to NCI PDQ and uses trials as a discussion prompt.

What to clarify

  • Which exact NRAS variant was reported?
  • Was BRAF also tested, and was it negative?
  • Did the report include tumor mutational burden, NTRK fusion, KIT, or other findings?
  • Is the oncologist treating this as cutaneous melanoma, mucosal melanoma, uveal melanoma, or another melanoma subtype?

Why clinical trials may come up

When a melanoma has an NRAS mutation, families often hear that targeted options are less straightforward than for common BRAF V600 melanoma. The safe next question is not "what should I choose?" but "should we search for NRAS-specific or mutation-informed trials?"

Useful trial-search anchors include the exact mutation term, prior treatment history, and the drug class being discussed. For example: "NRAS melanoma after PD-1 failure," "MEK inhibitor NRAS melanoma," and the exact medicine name if one has been proposed.

If PD-1 / PD-L1 stopped working

This is one of the hardest situations to organize. MatchMedi separates the conversation into buckets so families do not mix evidence from one drug into another:

  • Immunotherapy history: write down whether nivolumab, pembrolizumab, another PD-1/PD-L1 drug, or combination immunotherapy was used, and when it stopped helping.
  • NRAS trial search: search exact terms like "NRAS melanoma after PD-1 failure," "NRAS melanoma MEK inhibitor," and any drug name the doctor mentioned.
  • TIL therapy: in the United States, lifileucel has an FDA accelerated-approval context after prior PD-1 therapy for adult unresectable or metastatic melanoma, with additional prior-therapy context if BRAF V600 is positive.
  • China-specific MEK inhibitor pathway: tunlametinib / HL-085 is tracked separately because the approval and availability context is China-specific.
  • Lookalike trials: belvarafenib plus cobimetinib plus nivolumab is a sourced NRAS trial lead, but it is not tunlametinib plus nivolumab.

China-specific treatment questions

Some NRAS-mutant melanoma treatment discussions may involve country-specific medicines or trials. Tunlametinib / HL-085 / 妥拉美替尼 / 科露平 is tracked by MatchMedi as a China-specific MEK inhibitor topic after anti-PD-1/PD-L1 treatment failure. The official China NMPA English announcement describes conditional marketing approval with priority review for advanced melanoma with NRAS mutation after anti-PD-1/PD-L1 treatment failure. Availability outside China should not be assumed.

If a doctor proposes tunlametinib with nivolumab or pembrolizumab, ask whether the MEK inhibitor + PD-1 inhibitor combination is based on a trial, a local protocol, compassionate access, or off-label practice.

As of the latest source check, MatchMedi has found tunlametinib monotherapy trial records and a phase III trial comparing tunlametinib with investigator-chosen chemotherapy after prior immunotherapy. We have not yet found a melanoma trial record for the exact tunlametinib plus nivolumab combination, so that combination should be discussed as a specific physician/institution context unless a source is identified.

Response duration and resistance

Families often need language for a hard question: "What happens if this works, but only briefly?" Ask the oncology team how they define response, how often imaging or labs will be checked, what signs suggest progression, and whether taking a MEK inhibitor now could affect whether a later trial fits. MatchMedi uses source-linked wording such as "duration of response" and "progression-free survival" when those terms appear in trial records; it does not promise how long any individual response will last.

Questions to ask the oncology team

  • Are there NRAS-specific trials we should search for?
  • Should we consult a melanoma specialty center?
  • If immunotherapy is being discussed, what tells us whether it is working?
  • What prior treatments would affect whether a trial fits?
  • Would a repeat biopsy or updated genomic test change our options?
  • If tunlametinib is being discussed, is it being used alone, in a trial, or as part of a local/off-label combination?

Related MatchMedi pages